These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25518388)

  • 1. [Prevention of relapse of neuromyelitis optica (NMO)].
    Nomura K
    Nihon Rinsho; 2014 Nov; 72(11):2023-30. PubMed ID: 25518388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of neuromyelitis optica].
    Nomura K
    Nihon Rinsho; 2013 May; 71(5):829-38. PubMed ID: 23777090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment and clinical management of patients with neuromyelitis optica and anti-aquaporin 4 antibody].
    Ochi H
    Brain Nerve; 2010 Sep; 62(9):945-52. PubMed ID: 20844305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.
    Mealy MA; Wingerchuk DM; Palace J; Greenberg BM; Levy M
    JAMA Neurol; 2014 Mar; 71(3):324-30. PubMed ID: 24445513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis optica (Devic's syndrome).
    Wingerchuk DM; Weinshenker BG
    Handb Clin Neurol; 2014; 122():581-99. PubMed ID: 24507536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of neuromyelitis optica: an evidence based review.
    Sato D; Callegaro D; Lana-Peixoto MA; Fujihara K;
    Arq Neuropsiquiatr; 2012 Jan; 70(1):59-66. PubMed ID: 22218475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficiency of antibody therapy in demyelinating diseases.
    Akaishi T; Nakashima I
    Int Immunol; 2017 Jul; 29(7):327-335. PubMed ID: 28910968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis.
    Watanabe S; Misu T; Miyazawa I; Nakashima I; Shiga Y; Fujihara K; Itoyama Y
    Mult Scler; 2007 Sep; 13(8):968-74. PubMed ID: 17623727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of cases of neuromyelitis optica.
    Bomprezzi R; Postevka E; Campagnolo D; Vollmer TL
    Neurologist; 2011 Mar; 17(2):98-104. PubMed ID: 21364364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of rituximab on relapse rate and disability in neuromyelitis optica.
    Bedi GS; Brown AD; Delgado SR; Usmani N; Lam BL; Sheremata WA
    Mult Scler; 2011 Oct; 17(10):1225-30. PubMed ID: 21622594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.
    Miao J; Aboagye DE; Chulpayev B; Liu L; Ishkanian G; Kolanuvada B; Alaie D; Petrillo RL
    Am J Case Rep; 2018 Jan; 19():41-46. PubMed ID: 29321467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
    Miyamoto K; Kusunoki S
    Ther Apher Dial; 2009 Dec; 13(6):505-8. PubMed ID: 19954473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [NMO spectrum disorders and anti AQP4 antibody].
    Takai Y; Misu T; Takahashi T; Nakashima I; Fujihara K
    Brain Nerve; 2013 Apr; 65(4):333-43. PubMed ID: 23568981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuromyelitis optica and anti-aquaporin 4 antibody--distinct from multiple sclerosis].
    Misu T; Takahashi T; Nakashima I; Fujihara K; Itoyama Y
    Rinsho Byori; 2009 Mar; 57(3):262-70. PubMed ID: 19363997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of natalizumab to prevent relapses in neuromyelitis optica.
    Kleiter I; Hellwig K; Berthele A; Kümpfel T; Linker RA; Hartung HP; Paul F; Aktas O;
    Arch Neurol; 2012 Feb; 69(2):239-45. PubMed ID: 22332191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system.
    Argyriou AA; Makris N
    Acta Neurol Scand; 2008 Oct; 118(4):209-17. PubMed ID: 18336627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of NMO].
    Saida T
    Rinsho Shinkeigaku; 2009 Nov; 49(11):902-5. PubMed ID: 20030244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The spectrum of neuromyelitis optica (NMO) in childhood.
    Tillema JM; McKeon A
    J Child Neurol; 2012 Nov; 27(11):1437-47. PubMed ID: 22859697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica.
    Mok CC; To CH; Mak A; Poon WL
    J Rheumatol; 2008 Jan; 35(1):172-4. PubMed ID: 18176991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.